Exact Mass: 548.3937502
Exact Mass Matches: 548.3937502
Found 169 metabolites which its exact mass value is equals to given mass value 548.3937502
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Chenodeoxycholylarginine
Chenodeoxycholylarginine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylarginine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Arginine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylarginine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylarginine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylarginine
Deoxycholylarginine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylarginine consists of the bile acid deoxycholic acid conjugated to the amino acid Arginine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylarginine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylarginine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Cyclomicrophyllidine-A|Cyclomicrophyllin-A-benzoat|O-Benzoyl-cyclomicrophyllidin-A
(6R,8S,10S)-8-[(2Z)-3,7-dimethylocta-2,6-dien-1-yl]-2,6,7,8,9,10-hexahydro-2,2,7,7-tetramethyl-10-(3-methylbut-2-en-1-yl)-6-(2-methyl-1-oxobutyl)-6,10-methano-5H-cycloocta[b]pyran-5,11-dione|androforin A
3-Benzoyl-(3beta,5alpha,11alpha)-3,11-Dihydroxystigmast-7-en-6-one|Dihydrophysanol A|Physanol B
4-(dimethylamino)-N-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3S,9R,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
4-(dimethylamino)-N-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
(2-hydroxy-3-phosphonooxypropyl) (Z)-hexacos-15-enoate
[(E)-2-(heptanoylamino)-3-hydroxyhexadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-2-(butanoylamino)-3-hydroxynonadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-3-hydroxy-2-(octanoylamino)pentadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]nonyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-3-hydroxy-2-(tetradecanoylamino)non-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-3-hydroxy-2-(propanoylamino)icos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-2-acetamido-3-hydroxyhenicos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-3-hydroxy-2-(nonanoylamino)tetradec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-3-hydroxy-2-(pentadecanoylamino)oct-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-3-hydroxy-2-(pentanoylamino)octadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-2-(hexanoylamino)-3-hydroxyheptadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-2-(decanoylamino)-3-hydroxytridec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-2-(dodecanoylamino)-3-hydroxyundec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-3-hydroxy-2-(tridecanoylamino)dec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]decyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[(E)-3-hydroxy-2-(undecanoylamino)dodec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]octyl] 2-(trimethylazaniumyl)ethyl phosphate
C28H57N2O6P (548.3954031999999)
[1-carboxy-3-[3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-hydroxypropoxy]propyl]-trimethylazanium
C32H54NO6+ (548.3950924000001)
[1-carboxy-3-[3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-hydroxypropoxy]propyl]-trimethylazanium
C32H54NO6+ (548.3950924000001)
3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e,19e,21e)-3,7,12,16,20,24-hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,21,23-dodecaen-1-yl]-2,4,4-trimethylcyclohex-2-en-1-one
3,22-dihydroxy-4-methylergost-7-en-6-one; (3β,24ξ)-form,3-benzoyl
{"Ingredient_id": "HBIN006999","Ingredient_name": "3,22-dihydroxy-4-methylergost-7-en-6-one; (3\u03b2,24\u03be)-form,3-benzoyl","Alias": "NA","Ingredient_formula": "C36H52O4","Ingredient_Smile": "NA","Ingredient_weight": "548.8","OB_score": "NA","CAS_id": "57498-71-2","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8412","PubChem_id": "NA","DrugBank_id": "NA"}
3,4-Dehydrolycopen-16-al
{"Ingredient_id": "HBIN007331","Ingredient_name": "3,4-Dehydrolycopen-16-al","Alias": "3,4-dehydrolycopen-16-al; (2E,4Z,6E,8E,10Z,12Z,14E,16E,18E,20Z,22Z,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,4,6,8,10,12,14,16,18,20,22,24,26,30-tetradecaenal","Ingredient_formula": "C40H52O","Ingredient_Smile": "CC(=CCCC(=CC=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)C=CC=C(C)C=O)C)C)C)C","Ingredient_weight": "548.92","OB_score": "46.64445252","CAS_id": "NA","SymMap_id": "SMIT01127","TCMID_id": "4943","TCMSP_id": "MOL005486","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}